ELISA measurement of specific non-antigen-bound antibodies to Aβ1-42 monomer and soluble oligomers in sera from Alzheimer's disease, mild cognitively impaired, and noncognitively impaired subjects

Journal of Neuroinflammation

Volumn 8, Issue , 2011, Pages

  Klaver, Andrea C ^a   Coffey, Mary P ^a   Smith, Lynnae M ^a   Bennett, David A ^b,c   Finke, John M ^d   Dang, Loan ^d   Loeffler, David A ^a  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

^c RUSH UNIVERSITY MEDICAL CENTER   (United States)

^d OAKLAND UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN ANTIBODY; AMYLOID BETA PROTEIN[1-42]; MONOMER; OLIGOMER; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN (1 42); AMYLOID BETA-PROTEIN (1-42); ANTIBODY; PEPTIDE FRAGMENT;

AGED; ALZHEIMER DISEASE; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIGEN ANTIBODY COMPLEX; ANTIGEN BINDING; ARTICLE; BLOOD ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; MILD COGNITIVE IMPAIRMENT; NEUROPATHOLOGY; PILOT STUDY; TRANSMISSION ELECTRON MICROSCOPY; WESTERN BLOTTING; BLOOD; CHEMISTRY; COGNITIVE DEFECT; IMMUNOLOGY; METABOLISM; METHODOLOGY; PATHOPHYSIOLOGY; PROTEIN CONFORMATION;

AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANTIBODIES; COGNITION DISORDERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MILD COGNITIVE IMPAIRMENT; PEPTIDE FRAGMENTS; PILOT PROJECTS; PROTEIN CONFORMATION;

EID: 79961133787     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/1742-2094-8-93     Document Type: Article

References (41)

1. Hardy J, Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol Sci 1991, 12:383-388.
2. Weksler ME, Relkin N, Turkenich R, LaRusse S, Zhou L, Szabo P. Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals. Exp Gerontol 2002, 37:943-948. 10.1016/S0531-5565(02)00029-3, 12086704.
3. Moir RD, Tseitlin KA, Soscia S, Hyman BT, Irizarry MC, Tanzi RE. Autoantibodies to redox-modified oligomeric Abeta are attenuated in the plasma of Alzheimer's disease patients. J Biol Chem 2005, 280:17458-17463. 10.1074/jbc.M414176200, 15728175.
4. Brettschneider S, Morgenthaler NG, Teipel SJ, Fischer-Schulz C, Bürger K, Dodel R, Du Y, Möller HJ, Bergmann A, Hampel H. Decreased serum amyloid beta(1-42) autoantibody levels in Alzheimer's disease, determined by a newly developed immuno-precipitation assay with radiolabeled amyloid beta(1-42) peptide. Biol Psychiatry 2005, 57:813-816. 10.1016/j.biopsych.2004.12.008, 15820240.
5. Jianping L, Zhibing Y, Wei Q, Zhikai C, Jie X, Jinbiao L. Low avidity and level of serum anti-Abeta antibodies in Alzheimer disease. Alzheimer Dis Assoc Disord 2006, 20:127-132. 10.1097/00002093-200607000-00001, 16917180.
6. Song MS, Mook-Jung I, Lee HJ, Min JY, Park MH. Serum anti-amyloid-beta antibodies and Alzheimer's disease in elderly Korean patients. J Int Med Res 2007, 35:301-306.
7. Sohn JH, So JO, Hong HJ, Kim JW, Na DR, Kim M, Kim H, Nam E, Ha HJ, Kim YH, Mook-Jung I. Identification of autoantibody against beta-amyloid peptide in the serum of elderly. Front Biosci 2009, 14:3879-3883.
8. Hyman BT, Smith C, Buldyrev I, Whelan C, Brown H, Tang MX, Mayeux R. Autoantibodies to amyloid-beta and Alzheimer's disease. Ann Neurol 2001, 49:808-810. 10.1002/ana.1061, 11409436.
9. Baril L, Nicolas L, Croisile B, Crozier P, Hessler C, Sassolas A, McCormick JB, Trannoy E. Immune response to Abeta-peptides in peripheral blood from patients with Alzheimer's disease and control subjects. Neurosci Lett 2004, 355:226-230. 10.1016/j.neulet.2003.10.071, 14732472.
10. Mruthinti S, Buccafusco JJ, Hill WD, Waller JL, Jackson TW, Zamrini EY, Schade RF. Autoimmunity in Alzheimer's disease: increased levels of circulating IgGs binding Abeta and RAGE peptides. Neurobiol Aging 2004, 25:1023-1032. 10.1016/j.neurobiolaging.2003.11.001, 15212827.
11. Xu W, Kawarabayashi T, Matsubara E, Deguchi K, Murakami T, Harigaya Y, Ikeda M, Amari M, Kuwano R, Abe K, Shoji M. Plasma antibodies to Abeta40 and Abeta42 in patients with Alzheimer's disease and normal controls. Brain Res 2008, 1219:169-179.
12. Britschgi M, Olin CE, Johns HT, Takeda-Uchimura Y, LeMieux MC, Rufibach K, Rajadas J, Zhang H, Tomooka B, Robinson WH, Clark CM, Fagan AM, Galasko DR, Holtzman DM, Jutel M, Kaye JA, Lemere CA, Leszek J, Li G, Peskind ER, Quinn JF, Yesavage JA, Ghiso JA, Wyss-Coray T. Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer's disease. Proc Natl Acad Sci USA 2009, 106:12145-12150. 10.1073/pnas.0904866106, 2715538, 19581601.
13. Nath A, Hall E, Tuzova M, Dobbs M, Jons M, Anderson C, Woodward J, Guo Z, Fu W, Kryscio R, Wekstein D, Smith C, Markesbery WR, Mattson MP. Autoantibodies to amyloid beta-peptide (Abeta) are increased in Alzheimer's disease patients and Abeta antibodies can enhance Abeta neurotoxicity: implications for disease pathogenesis and vaccine development. Neuromolecular Med 2003, 3:29-39. 10.1385/NMM:3:1:29, 12665674.
14. Gruden MA, Davudova TB, Malisauskas M, Zamotin VV, Sewell RD, Voskresenskaya NI, Kostanyan IA, Sherstnev VV, Morozova-Roche LA. Autoimmune responses to amyloid structures of Abeta(25-35) peptide and human lysozyme in the serum of patients with progressive Alzheimer's disease. Dement Geriatr Cogn Disord 2004, 18:165-171. 10.1159/000079197, 15211072.
15. Gruden MA, Davidova TB, Malisauskas M, Sewell RD, Voskresenskaya NI, Wilhelm K, Elistratova EI, Sherstnev VV, Morozova-Roche LA. Differential neuroimmune markers to the onset of Alzheimer's disease neurodegeneration and dementia: autoantibodies to Abeta(25-35) oligomers, S100b and neurotransmitters. J Neuroimmunol 2007, 186:181-192. 10.1016/j.jneuroim.2007.03.023, 17477976.
16. Gustaw KA, Garrett MR, Lee HG, Castellani RJ, Zagorski MG, Prakasam A, Siedlak SL, Zhu X, Perry G, Petersen RB, Friedland RP, Smith MA. Antigen-antibody dissociation in Alzheimer disease: a novel approach to diagnosis. J Neurochem 2008, 106:1350-1356. 10.1111/j.1471-4159.2008.05477.x, 2575068, 18485104.
17. Gustaw-Rothenberg KA, Siedlak SL, Bonda DJ, Lerner A, Tabaton M, Perry G, Smith MA. Dissociated amyloid-beta antibody levels as a serum biomarker for the progression of Alzheimer's disease: a population-based study. Exp Gerontol 2010, 45:47-52. 10.1016/j.exger.2009.10.003, 2815174, 19819324.
18. Du Y, Dodel R, Hampel H, Buerger K, Lin S, Eastwood B, Bales K, Gao F, Moeller HJ, Oertel W, Farlow M, Paul S. Reduced levels of amyloid beta-peptide antibody in Alzheimer disease. Neurology 2001, 57:801-805.
19. Dodel R, Neff F, Noelker C, Pul R, Du Y, Bacher M, Oertel W. Intravenous immunoglobulins as a treatment for Alzheimer's disease: rationale and current evidence. Drugs 2010, 70:513-528. 10.2165/11533070-000000000-00000, 20329802.
20. Klaver AC, Finke JM, Digambaranath J, Balasubramaniam M, Loeffler DA. Antibody concentrations to Abeta1-42 monomer and soluble oligomers in untreated and antibody-antigen-dissociated intravenous immunoglobulin preparations. Int Immunopharmacol 2010, 10:115-119. 10.1016/j.intimp.2009.10.005, 19840873.
21. Klaver AC, Patrias LM, Coffey MP, Finke JM, Loeffler DA. Measurement of anti- Aβ1- 42 antibodies in intravenous immunoglobulin with indirect ELISA: the problem of nonspecific binding. J Neurosci Methods 2010, 187:263-269. 10.1016/j.jneumeth.2010.01.018, 20097229.
22. Dodel RC, Du Y, Depboylu C, Hampel H, Frölich L, Haag A, Hemmeter U, Paulsen S, Teipel SJ, Brettschneider S, Spottke A, Nölker C, Möller HJ, Wei X, Farlow M, Sommer N, Oertel WH. Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease. J Neurol Neurosurg Psychiatry 2004, 75:1472-1474. 10.1136/jnnp.2003.033399, 1738770, 15377700.
23. Relkin NR, Szabo P, Adamiak B, Burgut T, Monthe C, Lent RW, Younkin S, Younkin L, Schiff R, Weksler ME. 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. Neurobiol Aging 2009, 30:1728-1736. 10.1016/j.neurobiolaging.2007.12.021, 18294736.
24. Szabo P, Mujalli DM, Rotondi ML, Sharma R, Weber A, Schwarz HP, Weksler ME, Relkin N. Measurement of anti-beta amyloid antibodies in human blood. J Neuroimmunol 2010, 227:167-174. 10.1016/j.jneuroim.2010.06.010, 20638733.
25. Li Q, Gordon M, Cao C, Ugen KE, Morgan D. Improvement of a low pH antigen- antibody dissociation procedure for ELISA measurement of circulating anti-Abeta antibodies. BMC Neurosci 2007, 8:22. 10.1186/1471-2202-8-22, 1845169, 17374155.
26. Klatka LA, Schiffer RB, Powers JM, Kazee AM. Incorrect diagnosis of Alzheimer's disease. A clinicopathologic study. Arch Neurol 1996, 53:35-42.
27. Jellinger KA. Criteria for the neuropathological diagnosis of dementing disorders: routes out of the swamp?. Acta Neuropathol 2009, 117:101-110. 10.1007/s00401-008-0466-z, 19052757.
28. Walsh DM, Selkoe DJ. Oligomers on the brain: the emerging role of soluble protein aggregates in neurodegeneration. Protein Pept Lett 2004, 11:213-228. 10.2174/0929866043407174, 15182223.
29. Bennett DA, Schneider JA, Buchman AS, Mendes de Leon C, Bienias JL, Wilson RS. The Rush Memory and Aging Project: study design and baseline characteristics of the study cohort. Neuroepidemiology 2005, 25:163-175. 10.1159/000087446, 16103727.
30. Klaver AC, Patrias LM, Finke JM, Loeffler DA. Specificity and sensitivity of the Abeta oligomer ELISA. J Neurosci Methods 2011, 195:249-254. 10.1016/j.jneumeth.2010.12.001, 21163305.
31. Patrias LM, Klaver AC, Coffey MP, Finke JM, Digambaranath JL, Dang L, Martinez AA, Loeffler DA. Effects of external beam radiation on in vitro formation of Abeta1-42 fibrils and preformed fibrils. Radiat Res 2011, 175:375-381. 10.1667/RR2448.1, 21388281.
32. Du Y, Wei X, Dodel R, Sommer N, Hampel H, Gao F, Ma Z, Zhao L, Oertel WH, Farlow M. Human anti-beta-amyloid antibodies block beta-amyloid fibril formation and prevent beta-amyloid-induced neurotoxicity. Brain 2003, 126:1935-1939. 10.1093/brain/awg191, 12821522.
33. Dodel R, Balakrishnan K, Keyvani K, Deuster O, Neff F, Andrei-Selmer LC, Röskam S, Stüer C, Al-Abed Y, Noelker C, Balzer-Geldsetzer M, Oertel W, Du Y, Bacher M. Naturally occurring autoantibodies against {beta}-amyloid: investigating their role in transgenic animal and in vitro models of Alzheimer's disease. J Neurosci 2011, 31:5847-5854. 10.1523/JNEUROSCI.4401-10.2011, 21490226.
34. Istrin G, Bosis E, Solomon B. Intravenous immunoglobulin enhances the clearance of fibrillar amyloid-beta peptide. J Neurosci Res 2006, 84:434-443. 10.1002/jnr.20886, 16767774.
35. Legleiter J, Czilli DL, Gitter B, DeMattos RB, Holtzman DM, Kowalewski T. Effect of different anti-Abeta antibodies on Abeta fibrillogenesis as assessed by atomic force microscopy. J Mol Biol 2004, 335:997-1006. 10.1016/j.jmb.2003.11.019, 14698294.
36. O'Nuallain B, Acero L, Williams AD, Koeppen HP, Weber A, Schwarz HP, Wall JS, Weiss DT, Solomon A. Human plasma contains cross-reactive Abeta conformer- specific IgG antibodies. Biochemistry 2008, 47:12254-12256. 10.1021/bi801767k, 18956886.
37. Balakrishnan K, Andrei-Selmer LC, Selmer T, Bacher M, Dodel R. Comparison of intravenous immunoglobulins for naturally occurring autoantibodies against amyloid-beta. J Alzheimers Dis 2010, 20:135-143.
38. Bitan G, Lomakin A, Teplow DB. Amyloid beta-protein oligomerization: prenucleation interactions revealed by photo-induced cross-linking of unmodified proteins. J Biol Chem 2001, 276:35176-35184. 10.1074/jbc.M102223200, 11441003.
39. Storace D, Cammarata S, Borghi R, Sanguineti R, Giliberto L, Piccini A, Pollero V, Novello C, Caltagirone C, Smith MA, Bossù P, Perry G, Odetti P, Tabaton M. Elevation of {beta}-amyloid 1-42 autoantibodies in the blood of amnestic patients with mild cognitive impairment. Arch Neurol 2010, 67:867-872. 10.1001/archneurol.2010.137, 20625095.
40. Xia W, Yang T, Shankar G, Smith IM, Shen Y, Walsh DM, Selkoe DJ. A specific enzyme-linked immunosorbent assay for measuring beta-amyloid protein oligomers in human plasma and brain tissue of patients with Alzheimer disease. Arch Neurol 2009, 66:190-199. 10.1001/archneurol.2008.565, 19204155.
41. Sehlin D, Söllvander S, Paulie S, Brundin R, Ingelsson M, Lannfelt L, Pettersson FE, Englund H. Interference from heterophilic antibodies in amyloid-beta oligomer ELISAs. J Alzheimers Dis 2010, 21:1295-1301.